|
|
|
| Clinical Study of Rifabutin Combined with Antiviral in the Treatment of AIDS with Tuberculosis |
| HE Huawei, LU Xiangchan, HUANG Aichun, et al |
| The Fourth People's Hospital of Nanning, Guangxi Nanning 530023, China |
|
|
|
|
Abstract Objective: To explore rifabutin combined with antiviral drug clinical effect in the treatment of AIDS with tuberculosis. Methods: 80 AIDS patients with pulmonary tuberculosis admitted to our hospital from January 2014 to December 2015 were selected as the subjects of this study. According to the difference of clinical medication, they were divided into observation group and reference group. There were 40 cases in each group of two groups. The observation group was given the anti-tuberculosis regimen containing forbestine plus the anti-tuberculosis regimen containing efoviran or cleistogen, and the control group was given the anti-tuberculosis regimen containing rifampicin plus the anti-virus regimen containing efoviran. Both groups were given anti-tuberculosis and anti-HIV treatment. The anti-tuberculosis, anti-virus and total adverse reactions of the two groups were observed. Situation. Results: The effective rate of anti-tuberculosis treatment, negative rate of sputum examination, closure rate of pulmonary cavity and absorption of pulmonary lesions in the study group were significantly higher than those in the control group (P<0.05). There was no significant difference in the CD4+T lymphocyte between the two groups before treatment (P>0.05). After treatment, CD4 + T lymphocytes in both groups were significantly higher than those in the control group (P<0.05). The incidence of immune reconstitution inflammatory syndrome and total adverse reactions in the study group were significantly lower than those in the control group (P<0.05). Conclusion: Rifambutin combined with antiviral treatment of pulmonary tuberculosis with significant clinical effect, can effectively improve the cure rate of patients, reduce adverse reactions, reduce the incidence of immune reconstruction inflammatory syndrome, increase the anti-tuberculosis and antiviral efficacy.
|
|
|
|
|
|
[1] 叶涛,杨杰,杨声灼,等.艾滋病患者感染不同病原体后胸部CT特征及CD4+T细胞计数相关性分析[J].国际呼吸杂志,2015,25(4):253~256.
[2] 中华医学会感染病学分会艾滋病学组.HIV合并结核分枝杆菌感染诊治专家共识[J].中华临床感染病杂志,2017,10(2):81~90.
[3] Gao J, Zheng P, Fu H. Prevalence of TB/HIV co-infection in countries except China: a systematic review and meta-analysis[J]. Plos One, 2013, 8(5):e64915.
[4] 邓福英,陈蓉,刘寿荣,等.三种抗病毒药物联合用于艾滋病母婴传播26例预防效果观察[J].中国基层医药,2016,23(24):3786~3789.
[5] 林叶清,郭崇川.关于《中国结核病防治规划实施工作指南2008版》的改进思考[J].医学信息,2015,28(6):336.
[6] 中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南(第三版)[J].中华传染病杂志,2015,32(10):577~593.
[7] 殷继国,何卫华,练祖银,等.湖北省随州市艾滋病/肺结核病双重感染患者抗结核治疗与抗病毒治疗效果分析[J].中国预防医学杂志,2015,16(3):171~174.
[8] 罗惠倩,赵承杰,曹杨荣,等.利福布汀联合多种药物长效治疗耐多药肺结核疗效观察[J].中国药师,2015(3):464~466.
[9] 沈佳胤,卢洪洲.艾滋病合并结核病的防治研究进展[J].中国艾滋病性病,2015,20(6):543~546.
[10] 刘升,杜红,覃鸿发,等.不同抗病毒方案治疗艾滋病的临床疗效及不良反应分析[J].内科,2016,11(2):255~256.
[11] 杨栗坤,孙雯娜,王心静,等.结核分枝杆菌临床株对利福霉素类药物的耐药特点分析[J].传染病信息,2015(4):215~216.
[12] 罗惠倩,赵承杰,曹杨荣,等.利福布汀联合多种药物长效治疗耐多药肺结核疗效观察[J].中国药师,2015,18(3):464~466. |
|
|
|
2018, Vol. 24 
